Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Colorectal cancer (CRC) presents limited treatment options for advanced stages, necessitating novel therapeutic targets.
• Integrin-linked kinase (ILK) is a pseudo-kinase implicated in cancer progression, but its specific role in CRC remains unclear.
• Previous work identified a pro-inflammatory role for myeloid-specific ILK in colitis.

Purpose of the Study:

• To investigate the role of myeloid-specific ILK in the development and progression of colorectal cancer.
• To establish a correlation between chronic intestinal inflammation and CRC by examining myeloid ILK function in relevant mouse models.

Main Methods:

• Utilized mouse models of colitis-associated CRC and APC^min/+-driven CRC.
• Assessed tumor burden, macrophage polarization (M2), and T cell infiltration (CD8+, FOXP3+) in myeloid-ILK deficient and wild-type mice.
• Analyzed human CRC tissue microarrays for ILK+ myeloid cell expression.

Main Results:

• Myeloid ILK deficiency significantly reduced tumor burden in both CRC models.
• ILK deficiency impaired M2 macrophage polarization in vitro and decreased CD206+ TAMs in vivo.
• Myeloid ILK deficiency enhanced CD8+ T cell infiltration and reduced FOXP3+ T cells, elevating the CD8+/FOXP3+ ratio and suggesting an anti-tumor immune response.
• Elevated ILK+ myeloid cells were observed in human CRC tissues compared to normal tissues.

Conclusions:

• Myeloid-specific ILK is a novel driver of colorectal cancer progression.
• Targeting myeloid ILK may represent a potential therapeutic strategy for advanced CRC.
• Myeloid ILK influences tumor-associated macrophage polarization and anti-tumor T cell responses in CRC.